ALEXANDRIA, Va. – CancerLinQ LLC, a wholly-owned nonprofit subsidiary of the American Society of Clinical Oncology, has named three new members to its leadership team. David Dornstreich, Robert Merold, and Jennifer L. Wong recently joined CancerLinQ LLC and, in their various roles, will be utilizing their extensive strategic experience to fully realize CancerLinQ’s goal of unlocking real-world patient care data from millions of electronic health records and securely process and analyze the data to provide immediate quality feedback and personalized insights.
“We’re building a team of uniquely talented professionals to advance this big-data initiative,” said CancerLinQ CEO Kevin Fitzpatrick. “These three new team members will be leading our alliances throughout the oncology community. These collaborations are critical to achieving CancerLinQ’s goals of inclusiveness, engagement, and collegial exchange.”
Dornstreich, who will serve as Chief of Corporate Engagement, has more than 25 years of informatics experience with life science manufacturers, health information technology and advanced analytic organizations, as well as primary and secondary healthcare research groups. Prior to joining the CancerLinQ team, he spent five years at the American College of Cardiology (ACC) leading data commercialization efforts, including developing partnerships with Symphony Health Solutions and the National Heart Center of Singapore. Additionally, Dornstreich has successfully built and led sales and consulting teams at regional and national levels for a number of pharmaceutical manufacturers and market intelligence firms and was one of the pioneers in developing and commercializing longitudinal patient-level data while leading the business development team at Verispan.
Merold, who will serve as CancerLinQ’s Chief of Strategic Initiatives, brings more than 25 years’ experience in health care data, analytics, and enabling technologies. In the 1990s he developed and led the core information product suite for IMS Health still used today by all major Life Science companies, first in the U.S. and then 27 countries around the globe. He then ran successful start-ups in genomic/proteomic informatics. For the past decade he has consulted for a wide variety of organizations, most recently focused on applications of electronic medical record data, unstructured clinical data mining—including the IBM Watson oncology efforts—and working with medical society registries. Prior to working in the health care sector, Merold was a senior marketing and product executive at Procter & Gamble and Bristol-Myers Squibb.
Wong, CancerLinQ’s new Chief of Strategic Alliances, will establish and build relationships with key stakeholders, including other healthcare societies, governmental agencies, advocacy groups, oncology thought leaders, and innovation catalysts, forging the strong alliances, partnerships, and ventures critical to achieving CLQ’s promise of inclusiveness, collaboration, and collegial exchange. Prior to joining CancerLinQ, she served as the Director of Strategic Innovation and Clinical Ventures at the ACC and was the Managing Director of the Diabetes Collaborative Registry®, creating the first global, real-world, multi-specialty, big-data diabetes initiative with leading international academic, industry, and professional association partners from across the care continuum, and the PINNACLE Registry®, the largest ambulatory cardiovascular quality improvement registry in the United States. Wong also has worked in medical education at the Association of American Medical Colleges, cofounded an educational technology startup, and led national-scale admissions strategies at the Massachusetts Institute of Technology to identify, recruit, and advance talented students in their pursuit of science, technology, engineering, and mathematics fields.
CancerLinQ is a powerful database made up of vast amounts of usable, searchable, real-world cancer information. This national initiative will allow users to see trends among millions of patients by analyzing cancer patient medical records, uncovering patterns that can improve patient care, and enabling doctors to compare their care against that of their peers and recommended guidelines. The platform uses SAP HANA®, a flexible, multi-purpose data management and application platform created by SAP.
CancerLinQ is supported in part through the Conquer Cancer Foundation, whose generous donors have helped make the system possible. Major supporters include Amgen; Astellas; AstraZeneca; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cancer Treatment Centers of America®; Chan Soon-Shiong Family Foundation; Genentech BioOncology™; HELSINN; Janssen Oncology; Lilly; Novartis Oncology; Pfizer Oncology; Raj Mantena, RPh; Susan G. Komen®; and Thomas G. Roberts, Jr., MD, and Susan M. DaSilva. CancerLinQ is a project of CancerLinQ LLC. For more information, please visit CancerLinQ.org.
About CancerLinQ LLC
CancerLinQ LLC is a subsidiary of the American Society of Clinical Oncology established for the development and operation of the CancerLinQ™ initiative. CancerLinQ™ is a health information technology platform aimed at enhancing and improving the understanding and treatment of cancer. To learn more, visit www.cancerlinq.org.
Founded in 1964, the American Society of Clinical Oncology (ASCO) is the world’s leading professional organization representing physicians who care for people with cancer. With nearly 40,000 members, ASCO is committed to improving cancer care through scientific meetings, educational programs and peer-reviewed journals. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation, which funds ground-breaking research and programs that make a tangible difference in the lives of people with cancer. For ASCO information and resources, visit www.asco.org. Patient-oriented cancer information is available at www.cancer.net.